ASCEND: A Study of Cardiovascular Events iN Diabetes

• Status: Active, not recruiting
• Trial end date: 2037-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or supplementation with 1 gram daily omega-3 fatty acids or placebo prevents "serious vascular events" (i.e. non-fatal heart attack, non-fatal stroke or transient ischaemic attack, or death from vascular causes) in patients with diabetes who are not known to have occlusive arterial disease and to assess the effects on serious bleeding or other adverse events.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oxford
• Collaborators: Abbott; Abbott Products; Bayer; British Heart Foundation; Medical Research Council; Mylan; Solvay Pharmaceuticals
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Males or females with type 1 or type 2 diabetes mellitus.

• Aged ≥ 40 years.

• No previous history of vascular disease.

• No clear contra-indication to aspirin.

• No other predominant life-threatening medical problem.

Exclusion Criteria:

• Definite history of myocardial infarction, stroke or arterial revascularisation procedure.

• Currently prescribed aspirin, warfarin or any other blood thinning medication.